293 related articles for article (PubMed ID: 31843997)
1.
Morrissey I; Hawser S; Lob SH; Karlowsky JA; Bassetti M; Corey GR; Olesky M; Newman J; Fyfe C
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843997
[TBL] [Abstract][Full Text] [Related]
2.
Morrissey I; Olesky M; Hawser S; Lob SH; Karlowsky JA; Corey GR; Bassetti M; Fyfe C
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843999
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020.
Hawser S; Kothari N; Monti F; Morrissey I; Siegert S; Hodges T
J Glob Antimicrob Resist; 2023 Jun; 33():304-320. PubMed ID: 37207925
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study.
Tsai MH; Chen CL; Chang HJ; Chuang TC; Chiu CH
J Glob Antimicrob Resist; 2024 Jun; 37():93-99. PubMed ID: 38552878
[TBL] [Abstract][Full Text] [Related]
5. Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871
Ding L; Yang Y; Zheng C; Sun G; Han R; Guo Y; Yin D; Wu S; Zhu D; Hu F
Microbiol Spectr; 2022 Dec; 10(6):e0171522. PubMed ID: 36326536
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
[TBL] [Abstract][Full Text] [Related]
7.
Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).
Carvalhaes CG; Huband MD; Reinhart HH; Flamm RK; Sader HS
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617092
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.
Zhanel GG; Baxter MR; Adam HJ; Sutcliffe J; Karlowsky JA
Diagn Microbiol Infect Dis; 2018 May; 91(1):55-62. PubMed ID: 29338931
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
[TBL] [Abstract][Full Text] [Related]
11. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
13. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms.
Monogue ML; Thabit AK; Hamada Y; Nicolau DP
Antimicrob Agents Chemother; 2016 Aug; 60(8):5001-5. PubMed ID: 27353265
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
17. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
[TBL] [Abstract][Full Text] [Related]
18. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.
Mendes RE; Flamm RK; Farrell DJ; Sader HS; Jones RN
J Chemother; 2016 Apr; 28(2):83-8. PubMed ID: 26058844
[TBL] [Abstract][Full Text] [Related]
19. Eravacycline, a newly approved fluorocycline.
Lee YR; Burton CE
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1787-1794. PubMed ID: 31175478
[TBL] [Abstract][Full Text] [Related]
20. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
